Biomea Fusion, Inc.BMEAEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel covalent small molecule therapies for genetically defined cancers and other serious life-threatening diseases. Its lead pipeline candidates target key oncogenic drivers, addressing high unmet medical needs across global patient populations.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| FMR LLC | 15.00% | 5.4M | ▲ +0.99pp | 2024-02-09 |
| Thomas Butler | 10.40% | 3.8M | — | 2024-02-12 |
| Rainer M. Erdtmann | 7.80% | 2.8M | — | 2024-02-12 |
| BlackRock, Inc. | 6.00% | 2.2M | — | 2024-01-29 |
| Baker Bros. Advisors LP | 5.90% | 2.1M | — | 2024-02-14 |
| S.S. OR | 4.80% | 1.7M | — | 2024-02-12 |
| STATE STREET CORPORATION | 1.88% | 9.1K | ▼ -10.62pp | 2024-07-10 |
| Laurion Capital Management LP | 0.00% | 9.1K | ▼ -7.66pp | 2024-11-12 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.